News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Crinetics presented up to two-year PATHFNDR-1/2 data confirming PALSONIFY maintains durable acromegaly biochemical control.
  • IGF-1 levels remained stable and acromegaly symptoms were controlled across patients.
  • PALSONIFY stabilized or reduced pituitary tumor volume in the extension studies.
  • Patients switched from injectable therapies and previously untreated patients both showed durable responses.
  • Combining PALSONIFY with cabergoline improved biochemical control versus PALSONIFY alone.
  • No new safety signals were reported, supporting tolerability and market relevance of oral paltusotine.

Latest Articles

Goldman Sachs Shifts Focus Toward North Asia as AI-Driven Market Divergence Widens

Goldman Sachs Shifts Focus Toward North Asia as AI-Driven Market Divergence Widens

In a recent strategic assessment, Goldman Sachs has adjusted its regional equity outlook, signaling a strong preference for North Asian markets. The investment bank's analysts are leaning into regions characterized by robust earnings growth, specifically highlighting Taiwan and South Korea. This shift comes as the market experiences a significant p…

Teads CEO David Kostman Increases Personal Stake in Company Stock

Teads CEO David Kostman Increases Personal Stake in Company Stock

David Kostman, Chief Executive Officer of Teads Holding Co., recently augmented his personal investment by purchasing a total value of approximately $53,250 worth of company shares. These acquisitions occurred across three distinct dates in May and June 2026. Beyond the direct buying activity, the article details recent corporate actions at Teads, …

SpaceX Files for Eye-Popping $75 Billion IPO at $135 a Share

SpaceX Files for Eye-Popping $75 Billion IPO at $135 a Share

SpaceX plans to sell about 555.6 million new shares at $135 apiece to raise $75 billion in an initial public offering that targets a $1.75 trillion valuation. The offering consists entirely of new shares, with the company’s roadshow expected to begin this Thursday and earlier reports saying terms could be set as soon as Wednesday afternoon.

Director Thomas John Sells Shares of Genelux Stock

Director Thomas John Sells Shares of Genelux Stock

Thomas John, a director at GENELUX Corp (NASDAQ:GNLX), completed a stock sale totaling $29,801. The sale involved 10,000 shares of the company's common stock on June 1, 2026. While this transaction was executed through an established Rule 10b5-1 trading plan, which Mr. John initiated on June 4, 2025, the current market price for GNLX is noted at $2…

Figure Technology Solutions Reports May 2026 Operating Data

Figure Technology Solutions Reports May 2026 Operating Data

Figure Technology Solutions disclosed preliminary unaudited operating data for May 2026, highlighting a 135% year-over-year increase in Consumer Loan Marketplace Volume to $1.402 billion and sequential growth in $YLDS token circulation. The company emphasized its leadership in blockchain-native capital marketplaces, including its flagship products …

Analysis of Insider Activity and Corporate Developments at CoreWeave Inc.

Analysis of Insider Activity and Corporate Developments at CoreWeave Inc.

CoreWeave's director, Jack D. Cogen, recently executed a substantial sale of Class A Common Stock shares totaling over $29 million. Despite this insider transaction, the company continues to report strong market momentum, coupled with recent announcements regarding significant financing rounds, advanced technology integration, and positive analyst …

Director Sells Shares of Mirum Pharmaceuticals Following Vesting Event

Director Sells Shares of Mirum Pharmaceuticals Following Vesting Event

A director at Mirum Pharmaceuticals, Inc. executed a sale of company shares totaling $397,700 after an earlier vesting event. This transaction occurred against a backdrop of significant corporate activity, including the announcement of new convertible senior notes and elevated price targets from major research firms regarding its key drug candidate…

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

DBV Technologies has announced the screening of the first participant in its THRIVE Phase 2 clinical trial evaluating the safety and efficacy of the VIASKIN® Peanut Patch in infants aged 6 to 12 months with peanut allergy. This study builds on prior positive results in older children and aims to explore early intervention potential in the youngest …